Danske Bank raises doubts about Zealand Pharma's obesity candidate as a monotherapy
Danske Bank analyst Thomas Bowers sees more downside than upside risk to the trial data ahead of the results of a planned phase IIb study of Zealand Pharma’s obesity candidate.
by marketwire
The market’s expectations for Zealand Pharma’s obesity candidate, petrilintide, may be overstated based on existing trial data on amylin, says Danske Bank analyst Thomas Bowers in an analysis in which he casts doubt on amylin as a monotherapy for weight loss.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
